As of 2026-03-21, the EV/EBITDA ratio of Mirati Therapeutics Inc (MRTX) is -5.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRTX's latest enterprise value is 3,859.11 mil USD. MRTX's TTM EBITDA according to its financial statements is -723.54 mil USD. Dividing these 2 quantities gives us the above MRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.6x - 13.8x | 13.4x |
| Forward P/E multiples | 14.5x - 23.1x | 16.2x |
| Fair Price | (146.28) - (139.06) | (148.96) |
| Upside | -349.2% - -336.9% | -353.8% |
| Date | EV/EBITDA |